Literature DB >> 28475892

Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.

Davide F Robbiani1, Leonia Bozzacco2, Jennifer R Keeffe3, Ricardo Khouri4, Priscilla C Olsen5, Anna Gazumyan5, Dennis Schaefer-Babajew5, Santiago Avila-Rios6, Lilian Nogueira5, Roshni Patel5, Stephanie A Azzopardi2, Lion F K Uhl5, Mohsan Saeed2, Edgar E Sevilla-Reyes6, Marianna Agudelo5, Kai-Hui Yao5, Jovana Golijanin5, Harry B Gristick3, Yu E Lee3, Arlene Hurley5, Marina Caskey5, Joy Pai5, Thiago Oliveira5, Elsio A Wunder7, Gielson Sacramento4, Nivison Nery4, Cibele Orge4, Federico Costa8, Mitermayer G Reis8, Neena M Thomas5, Thomas Eisenreich5, Daniel M Weinberger9, Antonio R P de Almeida10, Anthony P West3, Charles M Rice2, Pamela J Bjorkman3, Gustavo Reyes-Teran6, Albert I Ko7, Margaret R MacDonald11, Michel C Nussenzweig12.   

Abstract

Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in individuals who develop high titers of anti-ZIKV antibodies, we screened cohorts in Brazil and Mexico for ZIKV envelope domain III (ZEDIII) binding and neutralization. We find that serologic reactivity to dengue 1 virus (DENV1) EDIII before ZIKV exposure is associated with increased ZIKV neutralizing titers after exposure. Antibody cloning shows that donors with high ZIKV neutralizing antibody titers have expanded clones of memory B cells that express the same immunoglobulin VH3-23/VK1-5 genes. These recurring antibodies cross-react with DENV1, but not other flaviviruses, neutralize both DENV1 and ZIKV, and protect mice against ZIKV challenge. Structural analyses reveal the mechanism of recognition of the ZEDIII lateral ridge by VH3-23/VK1-5 antibodies. Serologic testing shows that antibodies to this region correlate with serum neutralizing activity to ZIKV. Thus, high neutralizing responses to ZIKV are associated with pre-existing reactivity to DENV1 in humans.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Zika virus; antibodies; dengue virus; flavivirus; structure; vaccine

Mesh:

Substances:

Year:  2017        PMID: 28475892      PMCID: PMC5492969          DOI: 10.1016/j.cell.2017.04.024

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  76 in total

1.  Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein.

Authors:  David W C Beasley; Alan D T Barrett
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  The dengue group of viruses and its family relationships.

Authors:  A B SABIN
Journal:  Bacteriol Rev       Date:  1950-09

3.  Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.

Authors:  Karin Stettler; Martina Beltramello; Diego A Espinosa; Victoria Graham; Antonino Cassotta; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Stefano Jaconi; Federico Mele; Mathilde Foglierini; Mattia Pedotti; Luca Simonelli; Stuart Dowall; Barry Atkinson; Elena Percivalle; Cameron P Simmons; Luca Varani; Johannes Blum; Fausto Baldanti; Elisabetta Cameroni; Roger Hewson; Eva Harris; Antonio Lanzavecchia; Federica Sallusto; Davide Corti
Journal:  Science       Date:  2016-07-14       Impact factor: 47.728

4.  Immunogenic cross-talk between dengue and Zika viruses.

Authors:  Stephen C Harrison
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

5.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.

Authors:  T Geoff G Battye; Luke Kontogiannis; Owen Johnson; Harold R Powell; Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

6.  Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence.

Authors:  E A Henchal; M K Gentry; J M McCown; W E Brandt
Journal:  Am J Trop Med Hyg       Date:  1982-07       Impact factor: 2.345

7.  Zika Virus Infection in Pregnant Women in Rio de Janeiro.

Authors:  Patrícia Brasil; José P Pereira; M Elisabeth Moreira; Rita M Ribeiro Nogueira; Luana Damasceno; Mayumi Wakimoto; Renata S Rabello; Stephanie G Valderramos; Umme-Aiman Halai; Tania S Salles; Andrea A Zin; Dafne Horovitz; Pedro Daltro; Marcia Boechat; Claudia Raja Gabaglia; Patrícia Carvalho de Sequeira; José H Pilotto; Raquel Medialdea-Carrera; Denise Cotrim da Cunha; Liege M Abreu de Carvalho; Marcos Pone; André Machado Siqueira; Guilherme A Calvet; Ana E Rodrigues Baião; Elizabeth S Neves; Paulo R Nassar de Carvalho; Renata H Hasue; Peter B Marschik; Christa Einspieler; Carla Janzen; James D Cherry; Ana M Bispo de Filippis; Karin Nielsen-Saines
Journal:  N Engl J Med       Date:  2016-03-04       Impact factor: 91.245

8.  Epidemiology of dengue: past, present and future prospects.

Authors:  Natasha Evelyn Anne Murray; Mikkel B Quam; Annelies Wilder-Smith
Journal:  Clin Epidemiol       Date:  2013-08-20       Impact factor: 4.790

9.  Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.

Authors:  Florian Klein; Lilian Nogueira; Yoshiaki Nishimura; Ganesh Phad; Anthony P West; Ariel Halper-Stromberg; Joshua A Horwitz; Anna Gazumyan; Cassie Liu; Thomas R Eisenreich; Clara Lehmann; Gerd Fätkenheuer; Constance Williams; Masashi Shingai; Malcolm A Martin; Pamela J Bjorkman; Michael S Seaman; Susan Zolla-Pazner; Gunilla B Karlsson Hedestam; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2014-11-10       Impact factor: 14.307

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  145 in total

1.  Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.

Authors:  Shannon R Esswein; Harry B Gristick; Andrea Jurado; Avery Peace; Jennifer R Keeffe; Yu E Lee; Alisa V Voll; Mohsan Saeed; Michel C Nussenzweig; Charles M Rice; Davide F Robbiani; Margaret R MacDonald; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-22       Impact factor: 11.205

2.  The decline of dengue in the Americas in 2017: discussion of multiple hypotheses.

Authors:  Freddy Perez; Anthony Llau; Gamaliel Gutierrez; Haroldo Bezerra; Giovanini Coelho; Steven Ault; Sulamita Brandao Barbiratto; Marcelo Carballo de Resende; Lizbeth Cerezo; Giovanni Luz Kleber; Oscar Pacheco; Octavio Lenin Perez; Victor Picos; Diana P Rojas; Joao Bosco Siqueira; Marco Fidel Suarez; Eva Harris; Luis Gerardo Castellanos; Carlos Espinal; Jose Luis San Martin
Journal:  Trop Med Int Health       Date:  2019-01-28       Impact factor: 2.622

3.  A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates.

Authors:  Jennifer R Keeffe; Koen K A Van Rompay; Priscilla C Olsen; Qiao Wang; Anna Gazumyan; Stephanie A Azzopardi; Dennis Schaefer-Babajew; Yu E Lee; Jackson B Stuart; Anil Singapuri; Jennifer Watanabe; Jodie Usachenko; Amir Ardeshir; Mohsan Saeed; Marianna Agudelo; Thomas Eisenreich; Stylianos Bournazos; Thiago Y Oliveira; Charles M Rice; Lark L Coffey; Margaret R MacDonald; Pamela J Bjorkman; Michel C Nussenzweig; Davide F Robbiani
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

4.  A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein.

Authors:  Panke Qu; Chao Zhang; Min Li; Weimin Ma; Pei Xiong; Qingwei Liu; Gang Zou; Dimitri Lavillette; Feifei Yin; Xia Jin; Zhong Huang
Journal:  Cell Discov       Date:  2020-02-04       Impact factor: 10.849

Review 5.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine.

Authors:  Gavin Screaton; Juthathip Mongkolsapaya
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 6.  Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.

Authors:  James E Crowe
Journal:  Cell Host Microbe       Date:  2017-08-09       Impact factor: 21.023

Review 7.  Basics of memory B-cell responses: lessons from and for the real world.

Authors:  Rachel Wong; Deepta Bhattacharya
Journal:  Immunology       Date:  2018-11-29       Impact factor: 7.397

8.  Molecular Basis of a Protective/Neutralizing Monoclonal Antibody Targeting Envelope Proteins of both Tick-Borne Encephalitis Virus and Louping Ill Virus.

Authors:  Xu Yang; Jianxun Qi; Ruchao Peng; Lianpan Dai; Ernest A Gould; George F Gao; Po Tien
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

9.  Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope.

Authors:  Feng Long; Michael Doyle; Estefania Fernandez; Andrew S Miller; Thomas Klose; Madhumati Sevvana; Aubrey Bryan; Edgar Davidson; Benjamin J Doranz; Richard J Kuhn; Michael S Diamond; James E Crowe; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-14       Impact factor: 11.205

Review 10.  Zika virus vaccines: immune response, current status, and future challenges.

Authors:  Justin M Richner; Michael S Diamond
Journal:  Curr Opin Immunol       Date:  2018-05-10       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.